---
layout: default
title: Bevacizumab
parent: 僅模型預測 (L5)
nav_order: 79
evidence_level: L5
indication_count: 10
---

# Bevacizumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Bevacizumab: From Solid Tumors (Anti-VEGF Therapy) to Epiglottis Neoplasm

## One-Sentence Summary

Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor-A (VEGF-A), widely used globally for multiple solid tumors including colorectal cancer, non-small cell lung cancer, and ovarian cancer.
The TxGNN model predicts it may be effective for **Epiglottis Neoplasm**,
however, **no clinical trials** and **no publications** currently support this direction — this prediction is based on model inference alone.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in Saudi Arabia regulatory data (globally approved for multiple solid tumors) |
| Predicted New Indication | Epiglottis Neoplasm |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on publicly known information, bevacizumab (Avastin) is a recombinant humanized monoclonal antibody that binds specifically to VEGF-A, blocking its interaction with VEGF receptors (VEGFR-1 and VEGFR-2) on endothelial cells. This prevents tumor-associated angiogenesis — the formation of new blood vessels that tumors require for growth and metastasis. Its anti-tumor activity has been validated across colorectal cancer, non-small cell lung cancer, glioblastoma, ovarian cancer, cervical cancer, and renal cell carcinoma.

The theoretical link to epiglottis neoplasm rests on the general principle that solid tumors overexpress VEGF to sustain their vasculature. Head and neck squamous cell carcinomas, including those of the supraglottic larynx and epiglottis, do exhibit elevated VEGF expression in published biomarker studies. However, this biological rationale is generic and does not constitute disease-specific evidence.

Critically, the majority of epiglottis neoplasms are either benign (papillomas, commonly HPV-related) or are rare malignant variants. Benign papillomas are managed surgically; they lack the aggressive angiogenic drive seen in carcinomas for which bevacizumab was developed. No preclinical model, case report, or clinical trial has specifically evaluated bevacizumab in epiglottis neoplasm. The TxGNN score reflects graph-network proximity in a disease–drug interaction model, not direct empirical evidence.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for epiglottis neoplasm.

---

## Literature Evidence

Currently no related literature available for epiglottis neoplasm.

---

## Saudi Arabia Market Information

Bevacizumab has no approved licenses in Saudi Arabia (SFDA) based on current data. No authorizations on record.

---

## Cytotoxicity

Bevacizumab is an antineoplastic biologic agent (anti-VEGF monoclonal antibody) used for cancer treatment; the following cytotoxicity profile applies.

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted therapy — Anti-angiogenic monoclonal antibody (not conventional cytotoxic) |
| Myelosuppression Risk | Low (bevacizumab as a single agent does not typically cause clinically significant myelosuppression; risk increases when combined with cytotoxic chemotherapy) |
| Emetogenicity Classification | Low (monoclonal antibodies carry minimal emetogenic potential per standard classification) |
| Monitoring Items | Blood pressure (hypertension is a class effect), urinalysis for proteinuria (dipstick and 24-hr urine if ≥2+), CBC if used in combination regimens, renal function, wound assessment |
| Handling Protection | Standard aseptic biologic preparation required; cytotoxic drug handling regulations (closed-system transfer, PPE) are not mandated for monoclonal antibodies per most institutional policies, though local pharmacy SOPs should be consulted |

---

## Safety Considerations

Please refer to the package insert for safety information.

> Note: Bevacizumab carries well-characterized class-effect risks including hypertension, proteinuria, gastrointestinal perforation, impaired wound healing, arterial and venous thromboembolic events, and hemorrhage. Saudi Arabia SFDA-specific warning data was not available in this Evidence Pack; consult the approved SmPC or international labeling (EMA/FDA) for full prescribing guidance.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This prediction is classified as L5 — model-generated only, with zero supporting clinical trials and zero published literature specifically addressing bevacizumab in epiglottis neoplasm. The biological rationale is indirect and generic (VEGF inhibition in any tumor), and the target disease is predominantly benign (HPV-related papilloma) for which anti-angiogenic therapy has no established role.

**To proceed, the following is needed:**
- Disease classification clarification: determine whether the target is benign epiglottis papilloma vs. epiglottic squamous cell carcinoma, as the clinical justification and risk-benefit calculus differ substantially
- Biomarker evidence: VEGF/VEGFR expression data in epiglottis neoplasm tissue samples
- MOA gap remediation: retrieve full bevacizumab pharmacology from DrugBank API (DG002) and Saudi Arabia package insert warnings/contraindications (DG001) before any safety evaluation can proceed
- Exploratory literature search: expand search to head and neck carcinoma subtypes with epiglottis/supraglottic involvement using bevacizumab
- Regulatory pathway: Saudi Arabia SFDA registration of bevacizumab would need to precede any indication expansion work (currently 0 approvals)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

